| Parameter |
Non-diabetic |
Type-2 diabetic |
| Lean |
Overweight |
Obese |
Lean |
Overweight |
Obese |
| Total number (N) |
9 |
21 |
27 |
3 |
11 |
32 |
| Male (N) |
6 |
13 |
13 |
2 |
6 |
18 |
| Female (N) |
3 |
8 |
14 |
1 |
5 |
14 |
| Age (Yrs.) |
25-53 |
29-71 |
24-66 |
48-58 |
45-59 |
23-67 |
| Body mass index (kg/m2) |
22.611 ± 2.397 |
28.300 ± 1.144 |
34.701 ± 3.227 |
24.827 ± 1.144 |
28.829 ± 0.909 |
33.693 ± 2.566 |
| Percentage of body fat (PBF) |
27.300 ± 2.037 |
32.520 ± 1.182 |
39.280 ± 0.849 |
32.100 ± 4.400 |
31.840 ± 1.823 |
36.440 ± 1.018 |
| Glucose (mmol/L) |
4.948 ± 0.224 |
5.540 ± 0.326 |
5.387 ± 0.150 |
5.800 ± 0.3000 |
8.727 ± 0.707 |
8.708 ± 0.437 |
| Cholesterol (mmol/L) |
5.304 ± 0.394 |
4.913 ± 0.160 |
5.106 ± 0.213 |
5.400 ± 1.800 |
4.695 ± 0.511 |
5.160 ± 0.241 |
| High-density lipoprotein (mmol/L) |
1.630 ± 0.498 |
1.261 ± 0.289 |
1.174 ± 0.275 |
1.050 ± 0.181 |
1.138 ± 0.372 |
1.199 ± 0.285 |
| Low-density lipoprotein (mmol/L) |
3.378 ± 0.964 |
3.133 ± 0.671 |
3.374 ± 0.937 |
3.800 ± 1.510 |
2.582 ± 1.333 |
2.946 ± 1.092 |
| Triglycerides (mmol/L) |
0.616 ± 0.244 |
1.179 ± 0.626 |
1.200 ± 0.742 |
1.470 ± 0.967 |
1.791 ± 0.891 |
1.874 ± 1.494 |
| HbA1c (%) |
5.689 ± 0.483 |
5.845 ± 1.580 |
5.766 ± 0.589 |
7.733 ± 3.009 |
7.373 ± 1.547 |
8.206 ± 1.479 |
| Hyperlipidemia (N) |
0 |
0 |
3 |
0 |
3 |
5 |
| Coronary artery disease (N) |
0 |
0 |
1 |
0 |
1 |
1 |
| Lung disease (N) |
0 |
0 |
1 |
0 |
0 |
0 |
| Kidney disease (N) |
0 |
0 |
0 |
0 |
0 |
4 |
| Therapy |
|
Zocor, Aspirin |
Concor, Lipitor, Aspirin |
Metfornin, Aspirin |
Glucophage, Zocor, Januvia, Metformin, Aspirin, Zestril |
NovoRapid, Insulin, Aspirin, Zocor, Lipitor, Glucophage, Metformin, Zestril, Januvia |
|
